Evidence map›Paper›PMID 27438849›Full record

ArticleViruses2016

Molecular and Genetic Characterization of HIV-1 Tat Exon-1 Gene from Cameroon Shows Conserved Tat HLA-Binding Epitopes: Functional Implications.

Georges Teto, Julius Y Fonsah, Claude T Tagny, Dora Mbanya, Emilienne Nchindap, Leopoldine Kenmogne, Joseph Fokam, Dora M Njamnshi, Charles Kouanfack, Alfred K Njamnshi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Georges TetoDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198-5800, USA. georges.teto@unmc.edu.
Julius Y FonsahFaculty of Medicine and Biomedical Sciences, University of Yaoundé I, 1364 Yaoundé, Cameroon. yundze.fonsah@gmail.com.
Claude T TagnyFaculty of Medicine and Biomedical Sciences, University of Yaoundé I, 1364 Yaoundé, Cameroon. tayouclaude@yahoo.fr.
Dora MbanyaFaculty of Medicine and Biomedical Sciences, University of Yaoundé I, 1364 Yaoundé, Cameroon. dmbanya1@yahoo.co.uk.
Emilienne NchindapYaoundé University Teaching Hospital, 8046 Yaoundé, Cameroon. eminchindap4@yahoo.com.
Leopoldine KenmogneYaoundé University Teaching Hospital, 8046 Yaoundé, Cameroon. l.kemmogne@yahoo.com.
Joseph FokamFaculty of Medicine and Biomedical Sciences, University of Yaoundé I, 1364 Yaoundé, Cameroon. josephfokam@gmail.com.
Dora M NjamnshiHIV-Day Care Service, Yaoundé Central Hospital, 87, Yaoundé, Cameroon. dmnjamnshi@yahoo.co.uk.
Charles KouanfackFaculty of Medicine and Biomedical Sciences, University of Yaoundé I, 1364 Yaoundé, Cameroon. charleskouanfack@yahoo.fr.
Alfred K NjamnshiFaculty of Medicine and Biomedical Sciences, University of Yaoundé I, 1364 Yaoundé, Cameroon. aknjamnshi@yahoo.co.uk.
Georgette D KanmogneDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198-5800, USA. gkanmogne@unmc.edu.
Central Hospital of Yaoundé · CMUniversity Teaching Hospital of Yaounde · CMUniversité de Yaoundé I · CMUniversity of Nebraska Medical Center · USCentre International De Reference Chantal Biya · CM

Funding

HIV Genetic Diversity and Viral NeuropathogenesisR01MH094160 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KANMOGNE, GEORGETTE D. · 2012 to 2016
$3.1M
NeuroAIDS in Cameroon: Molecular determinantsR21MH080611 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KANMOGNE, GEORGETTE D. · 2007 to 2008
$368k
NIMH NIH HHS R01 MH094160NIMH NIH HHS R21 MH080611
6 · The paper itself

Abstract

HIV-1 Tat plays a critical role in viral transactivation. Subtype-B Tat has potential use as a therapeutic vaccine. However, viral genetic diversity and population genetics would significantly impact the efficacy of such a vaccine. Over 70% of the 37-million HIV-infected individuals are in sub-Saharan Africa (SSA) and harbor non-subtype-B HIV-1. Using specimens from 100 HIV-infected Cameroonians, we analyzed the sequences of HIV-1 Tat exon-1, its functional domains, post-translational modifications (PTMs), and human leukocyte antigens (HLA)-binding epitopes. Molecular phylogeny revealed a high genetic diversity with nine subtypes, CRF22_01A1/CRF01_AE, and negative selection in all subtypes. Amino acid mutations in Tat functional domains included N24K (44%), N29K (58%), and N40K (30%) in CRF02_AG, and N24K in all G subtypes. Motifs and phosphorylation analyses showed conserved amidation, N-myristoylation, casein kinase-2 (CK2), serine and threonine phosphorylation sites. Analysis of HLA allelic frequencies showed that epitopes for HLAs A*0205, B*5301, Cw*0401, Cw*0602, and Cw*0702 were conserved in 58%-100% of samples, with B*5301 epitopes having binding affinity scores > 100 in all subtypes. This is the first report of N-myristoylation, amidation, and CK2 sites in Tat; these PTMs and mutations could affect Tat function. HLA epitopes identified could be useful for designing Tat-based vaccines for highly diverse HIV-1 populations, as in SSA.

Indexed as

AdultCameroonConserved SequenceCross-Sectional StudiesEpitopesFemaleHIV-1HIV InfectionsHLA AntigensHumansMaleMiddle AgedPhylogenyProtein BindingProtein Processing, Post-TranslationalSequence Analysis, DNAEpitopesHLA Antigenstat Gene Products, Human Immunodeficiency VirusamidationCamerooncasein kinase-2HIV-1 genetic diversityHLA binding sitesN-myristoylationphosphorylationTat exon-1

Identifiers

PMID27438849
PMCPMC4974531
OpenAlexW2507065241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.